GlaxoSmithKline
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 4 Sell calls were followed by roughly flat moves (-0%) three months out.
- Recent price momentum is +4.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Hold.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2855 U.S. stocks StockVane covers.
Last computed: 2026-11-08 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 17.5x | Better than 54% |
| Forward P/E | 12.7x | Better than 66% |
| Price / Sales | 2.2x | Better than 55% |
| P/E vs own 5-yr range | 73rd pctl | Better than 35% |
Growth C-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 3.7% | Better than 42% |
| Net income CAGR (3Y) | -27.4% | Better than 12% |
| Free cash flow CAGR (3Y) | -2.6% | Better than 35% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 72.4% | Better than 85% |
| Operating margin | 25.5% | Better than 85% |
| Net margin | 17.5% | Better than 75% |
| Return on equity | 38.0% | Better than 91% |
| Return on invested capital | 19.3% | Better than 89% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -4.1% | Better than 52% |
| 6-month return | 1.7% | Better than 51% |
| 12-month return (ex latest month) | 3.3% | Better than 40% |
| Distance below 52-week high | 16.3% | Better than 60% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 0.8x | Better than 12% |
| Debt to assets | 29.0% | Better than 43% |
| Interest coverage | 11.8x | Better than 75% |
| Free cash flow / net income | 83.2% | Better than 27% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Price chart
Anonymous reader poll. Unscientific, not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 50.41
- Open
- 49.07
- Day range
- 48.94 - 50.74
- Avg price
- 50.19
- Volume
- 3.19M
- Turnover
- 159.86M
- Turnover ratei
- 0.16%
- Volume ratioi
- 0.83
- Amplitudei
- 3.57%
- 52-week rangei
- 44.64 - 60.12
Valuation
- P/Ei
- 13.48
- P/E (TTM)i
- 17.50
- P/Bi
- 4.00
- EPSi
- 3.73
- Book value / shi
- 12.58
- Net profit
- 7.48B
- Net assets
- 25.22B
Share structure
- Market cap
- 100.88B
- Float capi
- 97.78B
- Shares out
- 2.00B
- Float sharesi
- 1.94B
Dividend & listing
- Div yield (TTM)i
- 3.56%
- Dividend (TTM)
- 1.79
- Listing date
- 1970-01-01
16.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-82.28M net over the window
Short interest
- Shares short
- 14.58M
- % of floati
- 0.73%
- Days to coveri
- 2.14
- As of
- 2026-10-15
Frequently asked questions
What is the current stock price of GlaxoSmithKline (GSK)?
GlaxoSmithKline last traded at 50.33. The quote on this page refreshes every few seconds while US markets are open.
What is GlaxoSmithKline's market cap?
About 100.88B.
What is the P/E ratio of GlaxoSmithKline?
The trailing twelve-month P/E is 17.50, above its own 5-year average of 13.88 — toward the top of its historical range (73.39% percentile). See the Valuation tab for the full history.
Does GlaxoSmithKline pay a dividend?
Yes. The trailing dividend yield is 3.56%. The 2025 payout was up 9.4% from 2024. See the Dividends tab for the full payment history.
Is GlaxoSmithKline a buy according to analysts?
The consensus of 1 analysts is a Hold rating, with an average 12-month price target of 55.90, which implies 11.1% upside from the current price. This is not investment advice.
What is GlaxoSmithKline's StockVane Quant Rating?
The StockVane Momentum strategy currently rates GlaxoSmithKline a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-06 19:30:03 · For reference only, not investment advice and not tailored to your situation.
GlaxoSmithKline discussion 0 comments